Treatment with deferiprone (L1) in a thalassemic patient with bone lesions due to desferrioxamine

Journal of Pediatric Endocrinology and Metabolism

Volumn 13, Issue 6, 2000, Pages 677-680

  Mangiagli, A ^a   De Sanctis, Vincenzo ^b   Campisi, S ^a   Di Silvestro, G ^a   Urso, L ^b  

^a Department of Pediatrics ^*  (Italy)

^b UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

Bone lesions; Deferiprone; Thalassemia

Indexed keywords

DEFERIPRONE; DEFEROXAMINE;

ARTICLE; BONE LESION; BONE REGENERATION; CASE REPORT; DRUG EFFICACY; HUMAN; IRON CHELATION; KNEE RADIOGRAPHY; MALE; PRESCHOOL CHILD; THALASSEMIA;

BETA-THALASSEMIA; BODY HEIGHT; BONE DISEASES; DEFEROXAMINE; GROWTH DISORDERS; HUMANS; INFANT; IRON CHELATING AGENTS; KNEE; MALE; PYRIDONES;

EID: 0033947261     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Brittenham GM, Griffith PM, Nienhuis AW. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassaemia major. N Engl J Med 1994; 331: 567-573.
2. Giardina PJ, Grady RW. Chelation therapy in β thalassaemia: the benefits and limitation of desferrioxamine. Semin Hematol 1995; 32: 304-312.
3. De Virgilis S, Congia M, Frau A, Argiolu F, Diana G, Cucca F, Fodde M, Pirastu GF, Cao A. Deferoxamine-induced growth retardation in patients with thalassaemia major. J Pediatr 1988; 133: 661-669.
4. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996; 155: 368-372.
5. Naselli A, Vignolo M, Di Battista E, Mattei R, Aicardi G. Spondylometaphyseal abnormalities and severe short stature in a deferoxamine-treated homozygous betathalassaemia patient. Acta Med Auxol 1995; 27: 125-132.
6. Hartkamp MJ, Babyn PS, Olivieri F. Spinal deformities in deferoxamine-treated homozygous beta-thalassaemia major patients. Pediatr Radiol 1993; 23: 525-528.